tegilerdine

Tegilerdine (HS-10383) is a novel, potent small molecule μ-opioid receptor (MOR) agonist developed by Jiangsu Hengrui Pharmaceuticals. It is primarily designed for use in anesthesia and pain management, specifically as an analgesic adjunct during the induction of general anesthesia. Tegilerdine aims to provide rapid-onset analgesia with improved hemodynamic stability and a potentially lower incidence of adverse reactions, such as opioid-induced cough, compared to traditional opioids like sufentanil or fentanyl. Clinical trials, including those conducted at the First People's Hospital of Lianyungang, have evaluated its efficacy in preventing tracheal intubation-related complications and its overall safety profile in surgical settings.

Other names

tegilidine